Detection and Spread of Escherichia coli Possessing the Plasmid-Borne Carbapenemase KPC-2 in Brooklyn, New York

Bratu, Simona; Brooks, Steven E.; Burney, Sibte; Kochar, Sandeep; Gupta, Jayesh K.; Landman, David; Quale, John

doi:10.1086/512370

Cited by 109 publications

(69 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most important mechanism of resistance of carbapenems is the production of a carbapenemase enzyme, blaKPC. The gene for this enzyme is carried on a mobile piece of genetic material, which increases the risk for dissemination, even to other Enterobacteriaceae (23,24). The emergence and spread of CR-Kp underlines the need for immediate aggressive detection and control strategies to preserve their efficacy in the future (25).…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Carbapenem Resistant Klebsiella pneumoniae Hospital Infection in the Intensive Care Unit

Djordjevic

Folić

Gajovic

et al. 2018

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

Carbapenem-resistant Klebsiella pneumoniae (CR-Kp) has become a major threat to patients in hospitals, increasing mortality, length of stay and costs. e aim of this study was to discover risk factors for the development of hospital infections (HIs) caused by CR-Kp. A prospective cohort study was conducted in the Medical-Surgical Intensive Care Unit of the Clinical Centre in Kragujevac, Kragujevac, Serbia, from January 1, 2011, to December 31, 2015 (OR=1.080; p=0.045); previous use of carbapenems (OR=7.005; p=0.044); previous use of ciprofl oxacin (OR=20.628; p=0.007) and previous use of metronidazole (OR=40.320; p=0.011 p=0.046), dužina primene antibiotske terapije pre nastanka bolničke infekcije (OR=1.080; p=0.045), prethodna upotreba karbapenema (OR=7.005; p=0.044), prethodna upotreba ciprofl oksacina (OR=20.628; p=0.007) i prethodna upotreba metronidazola (OR=40.320; p=0.011

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Factors for Carbapenem Resistant Klebsiella pneumoniae Hospital Infection in the Intensive Care Unit

Djordjevic

Folić

Gajovic

et al. 2018

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

show abstract

“…seems to be an emerging public health problem in various parts of the world [30,38], although, to date, widespread hospital outbreaks have been reported mainly in the United States [11,26,46,51,[63][64][65][66][67] and Israel [8,43].…”

Section: Discussionmentioning

confidence: 99%

The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.

Sacha

Ostas²,

Jaworowska³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Antimicrobial resistance due to the continuous selective pressure from widespread use of antimicrobials in humans, animals and agriculture has been a growing problem for last decades. KPC β-lactamases hydrolyzed β-lactams of all classes. Especially, carbapenem antibiotics are hydrolyzed more efficiency than other β-lactam antibiotics. The KPC enzymes are found most often in Enterobacteriaceae. Recently, these enzymes have been found in isolates of Pseudomonas aeruginosa and Acinetobacter spp. The observations of bla KPC genes isolated from different species in other countries indicate that these genes from common but unknown ancestor may have been mobilized in these areas or that bla KPC -carrying bacteria may have been passively by many vectors. The emergence of carbapenem resistance in Gram-negative bacteria is worrisome because the carbapenem resistance often may be associated with resistance to many β-lactam and non-β-lactam antibiotics. Treatment of infections caused by KPC-producing bacteria is extremely difficult because of their multidrug resistance, which results in high mortality rates. Therapeutic options to treat infections caused by multiresistant Gram-negative bacteria producing KPC-carbapenemases could be used polymyxin B or tigecycline.

show abstract

“…Carbapenem resistance is currently rare among these, but expression of AmpC or class A (TEM or SHV-type) ESBLs plus loss of outer-membrane proteins have been observed in recent years [22]. Resistance to carbapenem has also been reported in E.coli-producing class B-beta lactamases (metallo-beta-lactamase) in various countries, including the USA and Greece [23,24]. In our study, 5.2% of the ESBL-producing strains were resistant to imipenem.…”

Section: Discussionmentioning

confidence: 99%

Cross-resistance and associated resistance in Escherichia coli isolates from nosocomial urinary tract infections between 2004–2006 in a Turkish Hospital

et al. 2008

View full text Add to dashboard Cite

AbstractIn this study, antimicrobial resistance profiles were determined for 748 isolates of Escherichia coli from patients with acute nosocomial urinary tract infections (UTIs) at a Turkish Training Hospital. Thirteen antibiotics were included. Resistance to ampicillin alone (45.1%) and ciprofloxacin alone (20.6%) were the most commonly identified ‘single resistances’. Multiple resistance was found in 49.7% of the strains. The most common multiple antibiotic resistance profiles included ampicillin-sulbactam/amoxycilline-clavulonate (4.0%) and ampicillin-sulbactam/trimethoprim-sulfamethoxazole/amoxycilline-clavulonate (2.8%). From 2004 to 2006, ampicillin, trimethoprim-sulfamethoxazole and ciprofloxacin resistant strains increased to 76% from 57%, 53% from 43% and 55% from 41%, respectively. The percentage of extended-spectrum β-lactamase (ESBL) producing strains was 7.8% and imipenem resistance was seen in 5.2% of ESBL positive strains. We conclude that clinically important E.coli strains have now emerged with broader multidrug resistance. Periodical evaluation of laboratory results and clinical surveillance are crucially important for optimal antibiotic management of UTIs and infection control policies.

show abstract

Detection and Spread of Escherichia coli Possessing the Plasmid-Borne Carbapenemase KPC-2 in Brooklyn, New York

Cited by 109 publications

References 25 publications

Risk Factors for Carbapenem Resistant Klebsiella pneumoniae Hospital Infection in the Intensive Care Unit

Risk Factors for Carbapenem Resistant Klebsiella pneumoniae Hospital Infection in the Intensive Care Unit

The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.

Cross-resistance and associated resistance in Escherichia coli isolates from nosocomial urinary tract infections between 2004–2006 in a Turkish Hospital

Contact Info

Product

Resources

About